Modafinil is best known as a wakefulness-promoting drug. That has led researchers and clinicians to consider whether it might help with two difficult symptoms seen in dementia: apathy and excessive daytime sleepiness.
The evidence is limited. A small Alzheimer’s disease trial found no added benefit for apathy, while two reports in dementia with Lewy bodies described worsening hallucinations and agitation after modafinil was introduced.
Key Takeaways
- Modafinil has been studied for apathy in Alzheimer’s disease and used experimentally for excessive daytime sleepiness in dementia with Lewy bodies.
- In a small randomized trial, modafinil did not improve apathy or daily functioning more than placebo.
- Two published cases linked modafinil with worsening hallucinations, agitation, sleeplessness, and manic behaviour in dementia with Lewy bodies.
- Becoming more awake does not necessarily mean better memory, motivation, or independence.
- Older adults may clear modafinil more slowly and can be more vulnerable to adverse effects and medication interactions.
Why Modafinil Comes Up in Dementia
Dementia can involve much more than memory loss. Depending on the type and stage, a person may also develop apathy, reduced initiative, excessive daytime sleepiness, fluctuating alertness, depression, agitation, hallucinations, or major changes in behaviour.
Apathy and sleepiness can look similar from the outside.
Someone with apathy may sit quietly, stop starting conversations, lose interest in hobbies, and need repeated prompting to begin routine tasks. Someone with excessive daytime sleepiness may appear equally inactive because they are drowsy or repeatedly falling asleep.
Modafinil appears relevant because it promotes wakefulness and affects brain systems involved in alertness and motivation. It is approved for narcolepsy, shift work sleep disorder, and excessive sleepiness associated with obstructive sleep apnoea, not for dementia.
What Is Apathy in Alzheimer’s Disease?
Apathy is mainly a loss of motivation, initiative, interest, and emotional responsiveness. A person may stop suggesting activities, show little interest in hobbies, speak less, or need repeated prompting despite being fully awake.
It is not the same as depression. Depression usually involves a disturbance in mood, such as sadness, guilt, hopelessness, worthlessness, or thoughts of death. Apathy can occur without those feelings.
Apathy can make Alzheimer’s disease harder to manage. It has been associated with poorer performance in basic and instrumental activities of daily living, including dressing, bathing, eating, walking, managing medication, and handling household tasks. Caregivers may misinterpret the person’s lack of initiation as deliberate indifference, which can add to frustration and burden.
Because modafinil can increase alertness and influence brain pathways involved in motivation, researchers tested whether it could reduce apathy in Alzheimer’s disease.
What Happened in the Alzheimer’s Trial?
Frakey and colleagues conducted a randomized, double-blind, placebo-controlled trial in 23 people with mild-to-moderate probable Alzheimer’s disease.
All participants had clinically significant apathy and were already taking a stable dose of a cholinesterase inhibitor. Some were also taking memantine or an antidepressant.
The modafinil group received 100 mg each morning for one week, followed by 200 mg each morning for seven weeks. The comparison group received placebo.
The researchers measured apathy, caregiver burden, daily functioning, and performance on practical everyday tasks.
Apathy scores improved in both groups over eight weeks. The people taking modafinil, however, did no better than those taking placebo. Modafinil also failed to improve activities of daily living on either caregiver reports or direct testing.
The authors concluded that adding modafinil to cholinesterase-inhibitor treatment did not provide an additional benefit for apathy or daily functioning.
One participant in the modafinil group left the study after developing increased motor tics. Otherwise, modafinil was described as generally well tolerated in this small sample.
Does That Rule Out Any Benefit for Apathy?
The trial was too small to exclude a minor effect with certainty.
Twenty-three people entered the study, and 22 were included in the final group comparison. The researchers calculated that a much larger sample would have been needed to detect a small or moderate treatment effect reliably.
The result still matters because this was the strongest direct test of modafinil for Alzheimer’s-related apathy. At 200 mg per day over eight weeks, it did not show a useful advantage over placebo.
It also highlights a practical distinction. A person may become more alert without becoming more interested, emotionally engaged, or able to begin tasks independently.
Sleepiness and Alertness in Lewy Body Dementia
Dementia with Lewy bodies often involves marked changes in alertness. A person may appear attentive at one time and profoundly drowsy or confused later.
Other common features include visual hallucinations, parkinsonism, REM sleep behaviour disorder, fluctuating cognition, and excessive daytime sleepiness.
These symptoms often overlap and can make treatment difficult. A drug that improves wakefulness may still worsen hallucinations or behaviour.
Modafinil was considered an attractive option because it promotes wakefulness and was thought to carry fewer behavioural risks than traditional stimulants.
The published cases raised doubts about that assumption.
What Happened in the Lewy Body Dementia Cases?
Prado and colleagues described two people with dementia with Lewy bodies who received modafinil for excessive daytime sleepiness.
The first case
The first patient was an 80-year-old man with cognitive decline, hypersomnolence, visual hallucinations, parkinsonian signs, and probable dementia with Lewy bodies.
He was started on modafinil 100 mg per day. Two days later, his hallucinations worsened. The dose was reduced to 50 mg, followed by a gradual reduction in psychotic symptoms.
Modafinil was later discontinued because hallucinations continued, and improvement was observed within a week.
Several months later, his caregiver gave him a single 200 mg dose so that he would be awake for a social event. He became agitated, developed an intense preoccupation with events from the past, and experienced more severe visual hallucinations. The symptoms gradually settled over the following week.
The second case
The second patient had probable dementia with Lewy bodies, visual hallucinations, delusions, behavioural fluctuations, REM sleep behaviour disorder, rigidity, and excessive daytime sleepiness.
After modafinil was introduced, he developed sleeplessness, agitation, loud and abusive behaviour, destructive behaviour in the home, and symptoms described as agitated mania.
His condition improved markedly after modafinil was discontinued.
These were case reports, not a controlled trial. They cannot show how often this reaction occurs or prove that modafinil was responsible for every behavioural change.
The timing was concerning in both cases. Symptoms appeared or worsened after modafinil was introduced and improved after it was stopped.
Modafinil should not be started, stopped, or adjusted without the prescribing clinician, particularly in someone with dementia, hallucinations, agitation, or several other medications.
Why Lewy Body Dementia May Carry More Risk
Hallucinations and psychosis are already common in dementia with Lewy bodies.
The condition involves abnormalities in several neurotransmitter systems, including dopamine and acetylcholine. Degeneration in these pathways may leave the brain unusually sensitive to medications that alter their activity.
Modafinil is sometimes described as an atypical or milder stimulant, but it still has dopaminergic effects. It binds to dopamine transporters and can increase dopamine levels in the brain. It also affects norepinephrine, histamine, orexin, glutamate, serotonin, and gamma-aminobutyric acid signalling.
The case report authors considered dopamine stimulation a plausible contributor to the agitation and psychosis they observed. They could not establish the exact mechanism.
For someone who already has visual hallucinations, delusions, severe agitation, mania, or major behavioural fluctuations, that uncertainty matters.
Does Modafinil Improve Memory or Mental Sharpness in Dementia?
The dementia studies reviewed here do not establish that modafinil improves memory.
The Alzheimer’s trial measured apathy, daily functioning, and caregiver burden. It was not designed to determine whether modafinil slowed cognitive decline or improved memory, language, reasoning, or executive function.
The Lewy body dementia paper focused on daytime sleepiness and worsening psychiatric symptoms. It did not demonstrate cognitive enhancement.
Modafinil has been studied as a cognitive enhancer in healthy people and in other neurological and psychiatric conditions, but its benefits are not consistent. The StatPearls review describes the benefits and risks of cognitive enhancement as uncertain.
A person who is less sleepy may perform better on a short task because they are awake enough to participate. That is not the same as reversing the cognitive impairment caused by Alzheimer’s disease, Lewy body disease, vascular injury, or another dementia.
Modafinil Risks in Older Adults With Dementia
Older adults may eliminate modafinil and its metabolites more slowly. The prescribing review advises considering lower doses and close monitoring in geriatric patients.
Common adverse effects include:
- headache
- nausea
- reduced appetite
- anxiety
- insomnia
- dizziness
More serious concerns include hallucinations, agitation, mania, psychosis, increased heart rate, increased blood pressure, and rare severe skin reactions.
Modafinil should be used cautiously in people with uncontrolled hypertension, unstable angina, recent myocardial infarction, structural heart disease, psychosis, or mania.
Drug interactions are another concern. Modafinil can change how the liver processes other medications, potentially lowering or increasing their concentrations.
Dementia care often involves several medications for cognitive, behavioural, sleep, cardiovascular, and other health problems. That makes a full medication review especially important before modafinil is added.
Apathy, Sleepiness, and Cognitive Decline Need Different Assessments
A person with dementia who appears withdrawn or inactive may have:
- apathy
- depression
- excessive daytime sleepiness
- poor nighttime sleep
- medication-related sedation
- delirium
- pain
- infection
- thyroid disease
- vitamin deficiency
- worsening dementia
- another neurological condition
Dementia reviews stress the need to look for treatable contributors to cognitive and behavioural decline. These can include sleep disorders, depression, medication effects, metabolic abnormalities, vitamin deficiencies, thyroid problems, infections, and vascular disease.
Giving a wakefulness drug without identifying the reason for the inactivity may miss the real problem.
Someone who sleeps during the day because of untreated sleep apnoea, sedating medication, fragmented nighttime sleep, or an infection does not need the same approach as someone with primary apathy.
Bottom Line
Modafinil has been considered in dementia because it promotes wakefulness and affects brain systems involved in alertness and motivation.
The strongest direct trial found that 200 mg per day did not improve apathy or daily functioning more than placebo in people with mild-to-moderate Alzheimer’s disease who were already taking cholinesterase inhibitors.
In dementia with Lewy bodies, two published cases linked modafinil with worsening hallucinations, agitation, sleeplessness, and manic behaviour. The reports are too small to define the overall risk, but they matter because people with Lewy body dementia are already vulnerable to psychosis.
The available evidence does not show that modafinil restores motivation, improves memory, or makes someone more independent in daily life.
References
Emmady, P. D., Schoo, C., & Tadi, P. (2022). Major neurocognitive disorder (dementia). In StatPearls. StatPearls Publishing.
Frakey, L. L., Salloway, S., Buelow, M., & Malloy, P. (2012). A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer’s disease. The Journal of Clinical Psychiatry, 73(6), 796–801. https://doi.org/10.4088/JCP.10m06708
Gale, S. A., Acar, D., & Daffner, K. R. (2018). Dementia. The American Journal of Medicine, 131(10), 1161–1169. https://doi.org/10.1016/j.amjmed.2018.01.022
Greenblatt, K., & Adams, N. (2023). Modafinil. In StatPearls. StatPearls Publishing.
Prado, E., Paholpak, P., Ngo, M., Porter, V., Apostolova, L. G., Marrocos, R., & Ringman, J. M. (2012). Agitation and psychosis associated with dementia with Lewy bodies exacerbated by modafinil use. American Journal of Alzheimer’s Disease & Other Dementias, 27(7), 468–473. https://doi.org/10.1177/1533317512456450
